Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AGIO |
---|---|---|
09:32 ET | 30477 | 51.67 |
09:34 ET | 13389 | 52.41 |
09:36 ET | 63159 | 52.775 |
09:38 ET | 13337 | 52.985 |
09:39 ET | 1400 | 52.74 |
09:41 ET | 8867 | 52.545 |
09:43 ET | 1800 | 52.65 |
09:45 ET | 14741 | 52.945 |
09:48 ET | 17464 | 52.7 |
09:50 ET | 1635 | 52.44 |
09:52 ET | 900 | 52.45 |
09:54 ET | 1291 | 52.305 |
09:56 ET | 11200 | 52.34 |
09:57 ET | 14287 | 51.695 |
09:59 ET | 850 | 51.75 |
10:01 ET | 11985 | 51.15 |
10:03 ET | 27985 | 51.59 |
10:06 ET | 4888 | 51.37 |
10:08 ET | 300 | 51.39 |
10:10 ET | 4826 | 50.98 |
10:12 ET | 11884 | 50.88 |
10:14 ET | 5008 | 50.5 |
10:15 ET | 24768 | 50.22 |
10:17 ET | 3813 | 50.25 |
10:19 ET | 13393 | 50.21 |
10:21 ET | 30247 | 50.39 |
10:24 ET | 7399 | 50.35 |
10:26 ET | 9748 | 50.32 |
10:28 ET | 5054 | 50.35 |
10:30 ET | 17996 | 50.225 |
10:32 ET | 2300 | 50.3 |
10:33 ET | 7492 | 50.48 |
10:35 ET | 900 | 50.59 |
10:37 ET | 4729 | 50.3376 |
10:39 ET | 2970 | 50.65 |
10:42 ET | 300 | 50.61 |
10:44 ET | 600 | 50.61 |
10:46 ET | 1751 | 50.42 |
10:48 ET | 300 | 50.49 |
10:50 ET | 4749 | 50.365 |
10:51 ET | 3442 | 50.25 |
10:53 ET | 2491 | 50.3 |
10:55 ET | 2908 | 50.335 |
10:57 ET | 7630 | 50.63 |
11:00 ET | 8151 | 50.69 |
11:02 ET | 7454 | 50.45 |
11:04 ET | 1446 | 50.44 |
11:06 ET | 7051 | 50.48 |
11:08 ET | 1211 | 50.43 |
11:09 ET | 2400 | 50.43 |
11:11 ET | 2313 | 50.59 |
11:13 ET | 27400 | 50.49 |
11:15 ET | 1840 | 50.61 |
11:18 ET | 133 | 50.54 |
11:20 ET | 300 | 50.56 |
11:22 ET | 10800 | 50.7 |
11:24 ET | 300 | 50.73 |
11:26 ET | 700 | 50.585 |
11:27 ET | 1708 | 50.595 |
11:29 ET | 300 | 50.73 |
11:31 ET | 1400 | 50.61 |
11:33 ET | 3319 | 50.72 |
11:36 ET | 10714 | 50.79 |
11:40 ET | 812 | 50.98 |
11:42 ET | 2450 | 51.01 |
11:44 ET | 1650 | 51.07 |
11:45 ET | 3196 | 50.95 |
11:47 ET | 27281 | 51.23 |
11:49 ET | 850 | 51.235 |
11:51 ET | 4880 | 51.125 |
11:54 ET | 6460 | 51.16 |
11:56 ET | 3384 | 51.155 |
11:58 ET | 11169 | 51.065 |
12:00 ET | 15452 | 51.015 |
12:02 ET | 10600 | 51 |
12:03 ET | 6497 | 51 |
12:05 ET | 61639 | 50.65 |
12:07 ET | 14255 | 51 |
12:09 ET | 36189 | 50.82 |
12:12 ET | 2630 | 50.685 |
12:14 ET | 1400 | 50.465 |
12:16 ET | 1055 | 50.28 |
12:18 ET | 78633 | 50.022 |
12:20 ET | 600 | 49.79 |
12:21 ET | 8262 | 49.14 |
12:23 ET | 6039 | 48.72 |
12:25 ET | 3379 | 48.69 |
12:27 ET | 465 | 48.3494 |
12:30 ET | 2993 | 48.02 |
12:32 ET | 750 | 47.89 |
12:34 ET | 6392 | 47.735 |
12:36 ET | 2792 | 47.7 |
12:38 ET | 7059 | 47.585 |
12:39 ET | 600 | 47.58 |
12:41 ET | 12479 | 48.31 |
12:43 ET | 1074 | 48.135 |
12:45 ET | 7747 | 48.095 |
12:48 ET | 900 | 48.11 |
12:50 ET | 2433 | 48.25 |
12:52 ET | 2123 | 48.115 |
12:54 ET | 2557 | 48.38 |
12:56 ET | 4628 | 48.55 |
12:57 ET | 2400 | 48.535 |
12:59 ET | 6719 | 48.74 |
01:01 ET | 1527 | 48.74 |
01:03 ET | 2288 | 49.11 |
01:06 ET | 3150 | 48.776 |
01:08 ET | 2600 | 48.8 |
01:10 ET | 6609 | 48.71 |
01:12 ET | 12513 | 48.355 |
01:14 ET | 5593 | 48.62 |
01:15 ET | 2650 | 48.76 |
01:17 ET | 392 | 48.825 |
01:19 ET | 10985 | 48.75 |
01:21 ET | 1791 | 48.7 |
01:24 ET | 1579 | 48.6075 |
01:26 ET | 3406 | 48.655 |
01:28 ET | 16846 | 48.31 |
01:30 ET | 1900 | 48.76 |
01:32 ET | 400 | 48.805 |
01:33 ET | 1600 | 48.92 |
01:35 ET | 100 | 48.815 |
01:39 ET | 300 | 48.685 |
01:42 ET | 5400 | 48.89 |
01:44 ET | 16905 | 49.005 |
01:46 ET | 900 | 49.02 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Agios Pharmaceuticals Inc | 2.8B | -7.6x | --- |
Iovance Biotherapeutics Inc | 2.8B | -5.5x | --- |
Geron Corp | 2.7B | -12.2x | --- |
IDEAYA Biosciences Inc | 2.6B | -14.0x | --- |
Xenon Pharmaceuticals Inc | 2.9B | -13.9x | --- |
Protagonist Therapeutics Inc | 2.7B | 17.0x | --- |
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8B |
---|---|
Revenue (TTM) | $31.3M |
Shares Outstanding | 56.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-6.49 |
Book Value | $14.50 |
P/E Ratio | -7.6x |
Price/Sales (TTM) | 89.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,293.88% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.